NGM Biopharmaceuticals’ aldafermin was granted FDA orphan status as a treatment of primary sclerosing cholangitis, according to a post to the agency’s website.
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See today’s best-performing stocks on TipRanks >>
Read More on NGM:
- NGM Biopharmaceuticals price target lowered to $3.50 from $7.00 at B. Riley
- NGM Bio Presents Positive Phase 2b Results from the ALPINE 4 Trial of Aldafermin in Patients with Compensated Cirrhosis (F4) Due to NASH at AASLD The Liver Meeting®
- NGM Biopharmaceuticals reports Phase 2b study results from ALPINE 4 trial
- NGM Biopharmaceuticals price target lowered to $4 from $9 at TD Cowen
- NGM Biopharmaceuticals reports Q3 EPS (35c), consensus (42c)